All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

TB-500 vs AOD-9604: Which Is Better?

TB-500 vs AOD-9604 comparison. Tissue repair vs fat loss. Different goals and when to choose each peptide.

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team||

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

TB-500 vs AOD-9604: Which Is Better? custom 2026 header image for Peptide Therapy
Custom header image for TB-500 vs AOD-9604: Which Is Better?, Peptide Therapy, and better treatment decision-making.
In This Article

This article is part of our Peptide Therapy collection. See also: GLP-1 Guides | Provider Comparisons

Search and AI answer brief

Practical answer: TB-500 vs AOD-9604: Which Is Better?

TB-500 vs AOD-9604 comparison. Tissue repair vs fat loss. Different goals and when to choose each peptide.

Short answer

TB-500 vs AOD-9604 comparison. Tissue repair vs fat loss. Different goals and when to choose each peptide.

Search intent

This page answers a specific Peptide Therapy question rather than a generic overview.

What to verify

semaglutide, peptide evidence quality

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

TB-500 vs AOD-9604 comparison. Tissue repair vs fat loss. Different goals and when to choose each peptide.

Quick Answer: TB-500 vs AOD-9604 compares a tissue healing peptide with a fat-loss peptide. TB-500 (Thymosin Beta-4) promotes wound healing, cell migration, and tissue repair throughout the body. AOD-9604 is a growth hormone fragment that stimulates fat breakdown without the growth-promoting effects of full GH. These peptides serve completely different purposes: TB-500 for healing and recovery, AOD-9604 for body composition improvement. Your choice depends on which goal is the priority .

Comparison

TB-500 vs AOD-9604
FactorTB-500AOD-9604
Primary roleTissue repair, systemic healingFat loss (lipolysis)
MechanismActin regulation, cell migrationGH fragment fat oxidation
Best forInjuries, wounds, cardiac repair, hairStubborn fat, body composition
Effect on healingStrong (primary application)None
Effect on fatNoneDirect lipolysis stimulation

When to Choose Each

  • TB-500: You have injuries, wounds, or tissue damage that needs repair. Also good for hair growth and cardiac support
  • AOD-9604: You want targeted fat reduction, particularly in stubborn areas
  • Both: Recovering athletes who need tissue healing while also improving body composition

Frequently Asked Questions

Can TB-500 help with body composition?

TB-500 doesn't directly affect fat metabolism. But by supporting tissue repair and reducing inflammation, it can help you return to full training capacity faster, which indirectly supports body composition goals through exercise.

AOD-9604

From the FormBlends catalog

AOD-9604

Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View AOD-9604 →
Popular Therapeutic Peptides by Use Case Clinical Interest Score 0 22 44 66 88 88 82 78 75 70 BPC-157 TB-500 Sermorelin Ipamorelin GHK-Cu Based on published peptide research literature
Popular Therapeutic Peptides by Use Case. Based on published peptide research literature.
View data table
Bar chart showing popular therapeutic peptides by use case: BPC-157 (88), TB-500 (82), Sermorelin (78), Ipamorelin (75), GHK-Cu (70)
CategoryClinical Interest ScoreDetail
BPC-15788Tissue repair and gut healing
TB-50082Injury recovery
Sermorelin78Growth hormone support
Ipamorelin75Anti-aging and recovery
GHK-Cu70Skin and tissue repair
Illustration for TB-500 vs AOD-9604: Which Is Better?

Is AOD-9604 as effective as semaglutide for weight loss?

No. Semaglutide produces significantly greater weight loss (15-20% body weight in trials). AOD-9604 provides more modest, localized fat reduction. For meaningful weight loss, GLP-1 agonists are more effective.

Medical References

  1. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. [PubMed | DOI]

Heal or Lean: We Help You Choose

At FormBlends, our physicians evaluate your goals and recommend the most effective peptide approach.

Schedule Your Free Consultation

Disclaimer: This article is for informational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider. Individual results may vary.

AOD-9604

Ready when you are

AOD-9604

Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View AOD-9604 →
Browse the full catalog →

Research Snapshot

Head-to-head comparison

Entities covered

Page type
Head-to-head comparison
FormBlends review
Last reviewed
2026-04-01
FormBlends review
FormBlends official source
Official source
Semaglutide evidence source
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

PubMed evidence trail

Research sources used to frame this page

For TB-500 vs AOD-9604: Which Is Better?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

ReviewAOD-9604 evidence2001

Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese and beta3-AR knockout mice

Mouse study; AOD9604 affected fat metabolism in mice, but the subsequent human obesity efficacy trial reported no meaningful weight loss versus placebo.

PubMed

ReviewAOD-9604 evidence2001

Increase of fat oxidation and weight loss in obese mice by a modified C-terminal GH fragment

Obese-mouse study of the AOD9604 fragment; preclinical only, and these effects were not reproduced in human obesity trials.

PubMed

ReviewAOD-9604 evidence2005

Gateways to clinical trials

Drug-pipeline review listing AOD-9604 in clinical development; it was later dropped after human obesity trials failed to show clinically meaningful weight loss.

PubMed

ReviewThymosin beta-4 evidence2007

beta-Thymosins

Background source for thymosin biology and tissue-repair mechanisms.

PubMed

ReviewThymosin beta-4 evidence2018

Thymosin beta 4 and the eye: the journey from bench to bedside

Shows how thymosin beta-4 evidence differs by route, tissue, and clinical application.

PubMed

ReviewThymosin beta-4 evidence2023

Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies

Used only for broad regenerative-medicine context, not as proof of consumer outcomes.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Emerging pharmacotherapies for obesity: A systematic review

Broad context for new and established obesity-drug categories.

PubMed

ReviewObesity pharmacotherapy evidence2026

Glucagon-like receptor agonists and next-generation incretin-based medications

Current review for incretin-based obesity medications and cardiometabolic effects.

PubMed

Systematic reviewObesity pharmacotherapy evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

Used as a class-level evidence anchor when no more specific citation group matches.

PubMed

Comparison decision path

Use this comparison to narrow the provider review question

Direct answer

TB-500 vs AOD-9604: Which Is Better? should help you decide which option deserves a clinical review, not force a one-size answer.

Evidence check

A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.

Safety check

The right choice can change based on history, medication interactions, side effects, budget, and availability.

Next step

After comparing, use the get-started flow to route your goals and health history into the right prescription review path.

FormBlends Editorial Context

Reviewed May 14, 2026

TB-500 vs AOD-9604 comparison. Tissue repair vs fat loss. Different goals and when to choose each peptide. Use "TB-500 vs AOD-9604: Which Is Better?" to make the conversation more specific before you choose a provider, product, or next step. The page leans into comparison and decision support and the details behind TB-500. Read the opening answer first, then check the evidence and safety sections before acting on the recommendation. The safest takeaway is a better checklist for clinician review, not a do-it-yourself medical decision.

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

Editorial refresh

Practical 2026 note for TB

TB now carries extra 2026 context around semaglutide, BPC-157, 500, aod, 9604, which, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.

Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to tb 500 vs aod 9604 which is better.

Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.

TB custom 2026 image for peptide therapy on FormBlends

Custom 2026 image for TB, peptide therapy, and better treatment decision-making.

Image description: Unique image for this page covering TB, peptide therapy, safety, cost, provider selection, and patient decision-making.

Download the Peptide Quick Reference Card

A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded GLP-1 medications starting at $99/month with free shipping.

Next Best Reads

Free Tools

Provider-informed calculators to support your weight loss journey.